New GBS vaccine trial aims to shield mothers and newborns
NCT ID NCT06611371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new vaccine designed to prevent Group B Streptococcus (GBS) infections, which can cause serious illness in newborns. About 600 healthy, non-pregnant women aged 18-49 in the US and South Africa will receive either the vaccine or a placebo. Researchers will check for side effects and measure the immune response to find the best dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROUP B STREPTOCOCCAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Grossman School of Medicine
New York, New York, 10016, United States
-
Wits Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), University of the Witwatersrand
Johannesburg, Gauteng, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.